Evidence map›Paper›PMID 39052947›Full record

ArticleJCO clinical cancer informatics2024

Identification of Novel DNA Methylation Prognostic Biomarkers for AML With Normal Cytogenetics.

Cândida Cardoso, Daniel Pestana, Sreemol Gokuladhas, Ana D Marreiros, Justin M O'Sullivan, Alexandra Binnie, Mónica TFernandes, Pedro Castelo-Branco

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO clinical cancer informatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Cândida CardosoFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve/Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Faro, Portugal.ORCID 0000-0002-7307-4567
Daniel PestanaFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve/Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Faro, Portugal.ORCID 0009-0001-9530-6349
Sreemol GokuladhasLiggins Institute, The University of Auckland, Auckland, New Zealand.ORCID 0000-0002-1685-0259
Ana D MarreirosFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve/Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Faro, Portugal.
Justin M O'SullivanFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve/Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Faro, Portugal.ORCID 0000-0003-2927-450X
Alexandra BinnieFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve/Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Faro, Portugal.ORCID 0000-0003-2969-8177
Mónica TFernandesAlgarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal.ORCID 0000-0002-1206-1367
Pedro Castelo-BrancoFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve/Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Faro, Portugal.ORCID 0000-0002-3453-3978

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAML is a hematologic cancer that is clinically heterogeneous, with a wide range of clinical outcomes. DNA methylation changes are a hallmark of AML but are not routinely used as a criterion for risk stratification. The aim of this study was to explore DNA methylation markers that could risk stratify patients with cytogenetically normal AML (CN-AML), currently classified as intermediate-risk. MATERIALS AND

methodsDNA methylation profiles in whole blood samples from 77 patients with CN-AML in The Cancer Genome Atlas (LAML cohort) were analyzed. Individual 5'-cytosine-phosphate-guanine-3' (CpG) sites were assessed for their ability to predict overall survival. The output was validated using DNA methylation profiles from bone marrow samples of 79 patients with CN-AML in a separate data set from the Gene Expression Omnibus.

resultsIn the training set, using DNA methylation data derived from the 450K array, we identified 2,549 CpG sites that could potentially distinguish patients with CN-AML with an adverse prognosis (

conclusionThis study highlights DNA methylation profiling as a promising approach to enhance risk stratification in patients with CN-AML, potentially offering a pathway to more personalized treatment strategies.

Indexed as

Biomarkers, TumorDNA MethylationLeukemia, Myeloid, AcuteAdultAgedAged, 80 and overCpG IslandsFemaleHumansMaleMiddle AgedPrognosisYoung AdultBiomarkers, Tumor

Identifiers

PMID39052947
PMCPMC11371081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.